anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1353635 Pharmaceutical compositions E R SQUIBB & SONS Inc 19 April 1971 [10 March 1970] 23097/71 Heading A5B [Also in Division C3] A composition useful as a demulcent or as a pharmaceutical carrier consists substantially of from 5% to 30% by weight of a hydrocolloid selected from cellulose derivatives, vegetable gums and animal proteins and 0.1 to 10% of an emulsifying agent, the balance being a mobile non-aqueous liquid selected from mineral oils, volatile hydrocarbons which are liquid at room temperature, fatty acid esters of polyhydric alcohols and C 3-10  fatty alcohols, in which the hydrocolloid is suspended, with or without the inclusion of flavouring and/or colouring agents. The hydrocolloid may be a cellulose ether e.g. methyl cellulose, a cellulose alkyl hydroxylate e.g. hydroxymethyl cellulose, a cellulose alkyl carboxylate e.g. carboxymethyl (or -ethyl) cellulose, an alkali metal salt of a cellulose alkyl carboxylate e.g. sodium carboxy methyl (or ethyl) cellulose, gum acacia, guar gum, gum tragacanth or gelatin. Diagnostic or therapeutic compositions comprise a diagnostic or therapeutic agent, and, as a carrier, the above composition. The diagnostic agent may be a radiopaque substance such as urografin acid (3, 5-diacetylamino-2, 4, 6-triiodobenzoic acid) or barium sulphate.
A method, computer system, and a computer program product for sequential pattern mining is provided. The present invention may include receiving a data mining parameter. The present invention may also include computing a plurality of frequent sequences without temporal annotations based on the received parameters. The present invention may then include extracting a subsequence with temporal annotations for each frequent sequence based on the computed plurality of frequent sequences. The present invention may further include clustering a plurality of temporal intervals using a time window based on the extracted subsequence. The present invention may also include producing an output based on the cluster of plurality of temporal intervals.
INTRODUCTION: Surgical procedures, even under local anesthesia, can induce significant stress and anxiety in patients. Innovative approaches to alleviate anxiety are crucial for improving patient outcomes. Sedatives and anxiolytics may alleviate this discomfort, but they can also subject patients to undesirable side effects, diminishing their overall effectiveness, and, finally, delaying discharge. We present the first case series of a patients underwent inguinal hernia surgical repair under local anesthesia using VRH (HypnoVR) to avoid use of sedatives and anxiolytics.
METHODS: 12 consecutive patients were enrolled to undergo elective monolateral inguinal hernia repair surgery via an open approach using HypnoVR, at Colorectal Surgery Unit of Fondazione Policlinico Universitario Campus Bio-Medico di Roma. Vital signs (heart rate, SpO2, blood pressure) were detected for all patients before surgery, during local anesthesia, during the whole intervention and after surgery.
RESULTS: No intraoperative or postoperative complications have been recorded and only one postoperative complication occurred (seroma), which not required invasive treatment but only drug administration. All patient's vital parameters were recorded during all operative and perioperative phasis. No use of intraoperative analgesic, sedative or anxiolytic were needed. All patients were discharged no later than 3 h after surgery.
CONCLUSION: Virtual Reality Hypnosis is a promising tool for anxiety management in surgical settings. Our series highlights the positive impact of HypnoVR in reduction and management of surgical patient anxiety and discomfort, allowing to perform inguinal hernia repair using only local anesthesia, with good patients' satisfaction.
FIELD: medicine, allergology, pharmacy. SUBSTANCE: invention relates to treatment of allergic and non-atopic diseases of eyes and nose. Invention relates to method for preparing composition by mixing sodium cromoline and/or other intal-like preparation, weight %/vol: 0.5-4.0; dexamethasone-21-phosphate sodium salt and/or other glucosteroid preparation, 0.05-0.1; ephedrine hydrochloride and/or other adrenostimulating agent, 1.0-5.0; sterile buffer solution, up to 100.0 with addition of neomycin sulfate or boric acid and/or other an antibacterial and an antiseptic agent. Invention provides the enhanced effectiveness and quality in production of drops. EFFECT: improved preparing method, valuable medicinal properties of drops, expanded assortment of used medicinal agents. 3 cl
After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours, 5-7 days apart. During each session, participants take 20 puffs over 10 minutes (one puff every 30 seconds) of vaporizer filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored, or salt-based nicotine e-liquid solution of tobacco flavor assigned in a random order.
Remote ischemic conditioning (RIC) has attracted much attention as a protective strategy for the heart and brain, although the underlying mechanisms remain unclear. We hypothesized that RIC enhances collateral circulation during cerebral ischemia through endothelial function and mitigates both early ischemic change and final infarct volume. We tested the RIC and sham procedure 30 min after permanent middle cerebral artery occlusion (MCAO) in male mice. Collateral circulation was examined during the procedure with 2D color-coded ultrasound imaging. Immediately after four cycles of RIC, early ischemic lesions on magnetic resonance imaging (MRI), diffusion-weighted imaging (DWI), and development of pial collateral vessels were examined. The neurological signs and infarct volume with TTC were examined until 48 h after daily RIC. As compared with sham procedure, RIC enhanced collateral circulation, diminished early ischemic lesions, enlarged pial collaterals, and mitigated infarct volume. Next, we examined the effect of inhibitor of nitric oxide synthase (NOS) and Akt on the beneficial effect of RIC in MCAO. Both allosteric Akt inhibitor, 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one (MK2206), and two NOS inhibitors, N5-(1-Iminoethyl)-L-ornithine dihydrochloride (L-NIO) and NG-Nitro-L-arginine methyl ester hydrochloride (L-NAME), counteracted the beneficial effect of RIC on collateral circulation, early lesions, pial anastomosis, and infarct volume. In permanent MCAO, RIC could enhance collateral circulation through leptomeningeal anastomosis with Akt-eNOS pathway and diminish early lesion and final infarct volume.
SHAM tDCS using tDCS device will be used for sham stimulation where the electrodes will be placed in the same positions as for anodal M1 stimulation, but the stimulator will be turned off after 90 seconds. Therefore, the patients feel the initial itching sensation but receive no current for the rest of the stimulation period.
Embodiments relate to the integration of a third-party application with a primary software platform and the integration of multiple different software platforms through user emulators that emulate user input operations. The user emulator enables interoperability between one or more software platforms by using the user emulator to communicate with primary software platforms while using application programming interfaces to interface with third-party applications. In an embodiment, first and second disparate software platforms are accessed. First sessions are initiated with the first and second software platform. First user input operations are emulated on the first software platform to receive a first page of information. A first format of the first page of information is converted to a second formed to write the converted page of information to the second software platform. The user emulator may write additional pages of information to the second software platform from additional software platforms.
The invention relates to regulatory sequences which impart a specific expression in dendritic cells. The regulatory sequences are isolated from the human fascin gene and also comprise, for example, promoter sequences. The invention also relates to recombinant nucleic acid molecules and vectors, which contain the regulatory sequences, and to preferred embodiments of the recombinant nucleic acid molecules and vectors, which code the antigens or immunoregulatory proteins. The invention additionally relates to host cells, which contain the recombinant nucleic acid molecules or vectors, and to methods for the production thereof. Additional embodiments relate to in-vitro methods for stimulating T cells and for producing T cell-stimulating dendritic cells, and to their formulation as medicaments. Additional medicaments are described which essentially relate to DNA vaccines and to gene-therapeutic medicaments, for example, for the immunization against and for the treatment of infectious diseases, tumors, allergies, Creutzfeldt-Jakob plaques or Alzheimer plaques. Additional inventive medicaments can be used for the targeted modulation of immune responses that is imparted by dendritic cells, for example, for treating autoimmune diseases or transplant rejection. Finally, the invention relates to different uses of the regulatory sequences.
Microencapsulation of ²-alanine uses ²-alanine as a core material and a mixture of a wall material and an additive as a release material. The additive comprises: a fatty acid-based saturated or unsaturated fatty acid glyceride containing 12-22 carbon atoms and a phospholipid. The fatty acid glyceride is a mono-fatty acid glyceride or a di-fatty acid glyceride, or a mixture formed by mixing the mono-fatty acid glyceride and the di-fatty acid glyceride at arbitrary proportions. The microencapsulation technique solves problems occurring with the use of ²-alanine as a raw material, such as high moisture absorption tendency thereof, unpleasant smell and stinging accompanying administration of the same. The invention selects and combines the wall material and the additive to attain a balance between embedment and release with respect to a microencapsulated ²-alanine product, and effectively optimizes release kinetics of the product, thereby enabling a stable release of the product, and realizing effective embedment and uniform release. Therefore, the microencapsulated ²-alanine is applicable to the preparation of food, drugs, health-enhancing products and functional food.
FIELD: cosmetics. SUBSTANCE: shaving gel contains water-soluble soap and volatile agent of prolonged foam-forming. The shaving gel may additionally have at least one complex monoester of aliphatic acid including 4-10 atoms of carbon and aliphatic alcohol having 16-18 atoms of carbon, and may comprise water-soluble gel-forming polymer. The proposed gel has improved properties, namely, better consistency and density, and also it spreads well over face skin and turns quickly in foam. EFFECT: improved characteristics. 16 cl, 3 ex
A method for improving a physiological condition ofa subject, e.g. a human or animal, is disclosed. The method comprises providing an audio signal to the subject, wherein the audio signal is associated with a virtual sound source having a shape and a position relative to the subject. The virtual sound source is defined by a plurality of virtual points, each virtual point having a position relative to the subject. The audio signal comprises audio signal components forthe respective virtual points of the virtual sound source, wherein each audio signal component has been determined based on the virtual position of its associated virtual point such that the audio signal is perceived by the subject as originating from the virtual sound source having said shape and said position relative to the subject. Further, a system for performing this method is also disclosed.
[Problem] To provide a p.o. medicine administration device with which: medicine and a viscous medium are made portable by being held separately; and when taking the medicine orally, after covering the individual medicines, a drug-covering medium in which the covered medicines are combined with the viscous medium can be easily formed and given orally. [Solution] The p.o. medicine administration device (100) comprises an outlet-forming junction (106). The outlet-forming junction (106) comprises a first inclined junction section (106a) and a second inclined junction section (106b). The first inclined junction section (106a) and the second inclined junction section (106b) have mutually differing angles of inclination. The first inclined junction section (106a) has a more gradual angle of inclination than the second inclined junction section (106b). The first inclined junction section (106a) also is formed on the open end (104)-side of the second inclined junction section (106b). By forming the first inclined junction section (106a) and the second inclined junction section (106b) of differing angles of inclination to be contiguous, it is possible to stably discharge a viscous medium of a specified size from the outlet.
Small-cell lung cancer (SCLC) is an aggressive tumor and most patients experienced relapse or progression after standard chemotherapy. Topotecan is active as second-line therapy for SCLC patients. However, even in sensitive patients, only 20% response rate and a median time to progression of 12 weeks are observed. New therapeutic options in SCLC are needed. Apatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor 2. It has been approved in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy. The efficacy of apatinib in SCLC is unknown. The purpose of this study is to determine whether topotecan plus apatinib are superior to topotecan alone as second-line therapy in small-cell lung cancer.
This is a post-market, prospective, non-significant risk, open-label, randomized multi-center clinical trial evaluating treatment with the LipiFlow System in patients with meibomian gland dysfunction prior to planned bilateral cataract surgery. All subjects undergo examination to determine study eligibility and to capture the Baseline status prior to surgery. Subjects are randomized to receive LipiFlow treatment (Pre-treatment group) one month before cataract surgery or no LipiFlow treatment (Untreated Control group). Cataract surgery is performed on both eyes of each subject with the second eye surgery completed within two months of the first eye. All subjects are evaluated at one month and three months after cataract surgery on the second eye with comparison of the study endpoints between the Pre-treatment and Untreated groups. To facilitate subject recruitment, the Untreated Control group receives crossover LipiFlow treatment for MGD (Post-treatment group) three months after cataract surgery on the second eye.
Hand-to-mouth task in the same conditions as the experimental arm but without vibratory feedback, only 3D movement analysis. The SWORD device is in place over the patient arm, performs continuous 3D movement analysis but does not provides vibratory feedback according to quality performance settings established by the clinician after patient assessment. If movement is of lower amplitude or slower than prescribed NO vibratory stimulus is delivered at the wrist of the patient. The intervention is repeated on the hemiparetic and normal sides and the duration of the task is defined according to the patient cardiovascular status.
BACKGROUNDLeft ventricular hypertrophy (LVH) and dyslipidemia are strong, independent predictors for cardiovascular disease, but their relationship is less well studied. A longitudinal lipidomic profiling of left ventricular mass (LVM) and LVH is still lacking.METHODSUsing liquid chromatography-mass spectrometry (LC-MS), we repeatedly measured 1,542 lipids from 1,755 unique American Indians attending 2 exams (mean, 5 years apart). Cross-sectional associations of individual lipid species with LVM index (LVMI) were examined by generalized estimating equation (GEE), followed by replication in an independent biracial cohort (65% White, 35% Black). Baseline plasma lipids associated with LVH risk beyond traditional risk factors were identified by logistic GEE model in American Indians. Longitudinal associations between changes in lipids and changes in LVMI were examined by GEE, adjusting for baseline lipids, baseline LVMI, and covariates.RESULTSMultiple lipid species were significantly associated with LVMI or the risk of LVH in American Indians. Some lipids were confirmed in Black and White individuals. Moreover, some LVH-related lipids were inversely associated with risk of coronary heart disease (CHD). Longitudinal changes in several lipid species were significantly associated with changes in LVMI.CONCLUSIONAltered fasting plasma lipidome and its longitudinal change over time were significantly associated with LVMI and risk for LVH in American Indians. Our results offer insight into the role of individual lipid species in LV remodeling and risk of LVH, independent of known risk factors.FUNDINGThis study was supported by the NIH grant (R01DK107532). The Strong Heart Study has been funded in whole or in part with federal funds from the National Heart, Lung, and Blood Institute, NIH, Department of Health and Human Services, under contract nos. 75N92019D00027, 75N92019D00028, 75N92019D00029, and 75N92019D00030.
In clinical studies, simvastatin did not impair adrenal reserve or significantly reduce basal plasma cortisol concentration. Small reductions from baseline in basal plasma testosterone in men were observed in clinical studies with simvastatin, an effect also observed with other inhibitors of HMG-CoA reductase and the bile acid sequestrant cholestyramine. There was no effect on plasma gonadotropin levels. In a placebo-controlled, 12-week study there was no significant effect of simvastatin 80 mg on the plasma testosterone response to human chorionic gonadotropin (hCG). In another 24-week study, simvastatin 20 to 40 mg had no detectable effect on spermatogenesis. In 4S, in which 4,444 patients were randomized to simvastatin 20 to 40 mg/day or placebo for a median duration of 5.4 years, the incidence of male sexual adverse events in the two treatment groups was not significantly different. Because of these factors, the small changes in plasma testosterone are unlikely to be clinically significant. The effects, if any, on the pituitary-gonadal axis in pre-menopausal women are unknown.
A method for generating a software-implemented module for determining a glucose value in a body fluid. A first set of input data indicative of first values measured for first and a second input parameters is provided. A second set of input data indicative of second values for the first and second input parameters is also provided. The first and second sets of input data are processed by a physiological model to determine first and second sets of glucose values, respectively, in a body fluid. Training data is determined and a set of test data different from the training data is also determined. A software-implemented machine learning model configured to determine a glucose value in a body fluid of a patient is provided and is trained by the training data and is tested by the test data.
PURPOSE OF REVIEW: This review evaluates recent advancements in disease-modifying therapies for axial spondyloarthritis (axSpA).
RECENT FINDINGS: A recent study could not demonstrate an additional effect of NSAID therapy on golimumab [Tumor Necrosis Factor-α inhibitor (TNFi)] on structural progression; however, this might be due to the fact that the study was underpowered. While DMARDs have shown promise in suppressing inflammation, their impact on structural progression remains uncertain. A well powered trial showed no difference in spinal progression between secukinumab [Interleukin17A inhibitor (IL17Ai)] and adalimumab-biosimilar (TNFi). Preliminary data on Janus kinase inhibitors (JAKi) focus on MRI findings but lack evidence on radiographic spinal progression. While some studies suggest promising outcomes, others reveal limitations and inconclusive findings.
SUMMARY: Recent studies explore the effectiveness of NSAIDs, biological disease-modifying antirheumatic drugs like TNFi and IL-17i, as well as JAK inhibitors in axSpA. Conflicting evidence surrounds these therapies' ability to impede structural progression, with challenges in study design and interpretation. Moreover, changes in demographics and treatment methods underscore the importance of examining trends over time when assessing disease outcomes. Ultimately, ongoing research could benefit from new imaging tools when evaluating therapeutic strategies for modifying disease progression in axSpA.
OBJECTIVES: I. Determine the overall response rate, onset and duration of partial and complete responses, and duration of stable disease in patients with recurrent metastatic colorectal cancer treated with oxaliplatin. II. Determine the overall survival of patients treated with this drug. III. Determine the proportion of patients with tumor-related symptomatic improvement and time to tumor-related symptomatic worsening in patients treated with this drug. IV. Determine the time to disease progression in patients treated with this drug. V. Determine the proportion of patients achieving stable disease when treated with this drug. VI. Determine the safety of this drug in this patient population.

OUTLINE: This is a multicenter study. Patients receive oxaliplatin IV over 120 minutes on day 1. Courses repeat every 3 weeks for up to 1 year in the absence of disease progression. Patients are followed at 30 days and then every 8 weeks for 10 months.

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Patients will take ENZ at a dose of 160 mg PO once daily (QD), beginning on Day 1, of Week 1. Patients will take ENZ throughout planned treatment period or withdrawal of consent or progression of disease requiring change in therapy.
Online Bystander Training or Haven provides students with definitions and statistics associated with sexual assault and relationship violence, bystander skills and strategies, and campus policies and resources. The trainings are "personalized and reflective" and incorporate the student's "unique perspectives and experiences." This 45-minute training is mandatory and students are asked to complete a follow-up survey 45-days after the training. Because this training is mandatory for all incoming students, all students are expected to have exposure to this training.
FIELD: medical engineering. SUBSTANCE: method involves perforating injured sinus at the typical puncture place, its rinsing and filling with drug solution, exposing to low frequency ultrasonic treatment and removing the used solution. After having been perforated having been perforated with puncture needle and sinuses rinsed, the puncture hole is widened and after removing the used solution, aerosol jet antiseptic spray coating and laser radiation are additionally applied at the stage of granulation and epithelialization of the pathologic focus. The device has power supply source, acoustic unit and emitter for intranasal application to pathologic focus and is additionally provided with limiting needle having rest flange where emitter is axially movably placed forming coaxial space between the internal diameter of the needle and external diameter of the emitter communicating with hydraulic system for supplying and discharging medicinal drug solution through cavity in guiding bushing and rest flange. Fixing screw is made in the guiding bushing. The coupled groove is manufactured in the cylindric portion of the radiator. EFFECT: accelerated treatment course. 6 cl, 3 dwg
This is a split mouth study. This group received 2 sessions of Micro-osteoperforation (MOP) at an interval of 8 weeks.